Author:
Kalfazade Nadir,Kuskucu Ahmet M.,Karadag Serdar,Sahin Selcuk,Aras Bekir,Midilli Kenan,Yılmaz Gülden,Tasci Ali I
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Greenlee RT, Landis SH, Murray T, Bolden S, Wingo PA (2000) Cancer Statistics. CA Cancer J Clin 50:7–33. doi: 10.3322/canjclin.50.1.7
2. Bai XZ, Masters JR, O’Donoghue N, Kirby R, Pan LX, Young M et al (1999) Prognostic markers in clinically localized prostate cancer. Int J Oncol 14:785–791
3. Megean A, Vona G, Nalpas B, Damotte D, Brousse N, Chretein Y et al (2000) Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumour recurrence. J Urol 163:2022–2029. doi: 10.1016/S0022-5347(05)67621-5
4. Lerner SP, Seale-Hawkins C, Carlton CR Jr, Scardino PT (1991) The risk of dying prostate cancer in patients clinically localized disease. J Urol 146:1040–1045
5. Prostate Cancer Trialists’ Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 335:1491–1498. doi: 10.1016/0140-6736(90)93030-S
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献